Samalin Investment Counsel LLC Reduces Holdings in Eli Lilly and Company $LLY

Samalin Investment Counsel LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 46.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 784 shares of the company’s stock after selling 667 shares during the quarter. Samalin Investment Counsel LLC’s holdings in Eli Lilly and Company were worth $612,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth about $27,000. Blume Capital Management Inc. raised its holdings in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $35,000. TD Capital Management LLC lifted its stake in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. Finally, Iron Horse Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 100.0% during the 1st quarter. Iron Horse Wealth Management LLC now owns 66 shares of the company’s stock worth $55,000 after purchasing an additional 33 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 4,314 shares of company stock worth $2,766,929 over the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $923.35 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $955.46. The business’s fifty day simple moving average is $799.97 and its 200-day simple moving average is $775.01. The firm has a market cap of $872.92 billion, a PE ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. UBS Group increased their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Morgan Stanley reduced their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $983.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.